Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David A Sallman

Showing results (11-20 of 164) with videos related to

Pageof 17
Sort By:
Cancer Journal (Sudbury, Mass.)|January 24, 2022
What Are the Prospects for Treating TP53 Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia?Chen Wang, David A Sallman
Current Treatment Options in Oncology|March 25, 2023
Current Therapeutic Landscape in Lower Risk Myelodysplastic SyndromesChen Wang, David A Sallman
Blood|September 5, 2024
TP53-mutated acute myeloid leukemia: how can we improve outcomes?David A Sallman, Maximilian Stahl
Leukemia & Lymphoma|November 26, 2022
Therapeutic approaches for the management of higher risk myelodysplastic syndromesChen Wang, David A Sallman
Hematology. American Society of Hematology. Education Program|December 9, 2023
Frontline treatment options for higher-risk MDS: can we move past azacitidine?David A Sallman, Zhuoer Xie
Haematologica|June 2, 2017
Myelodysplasia in younger adults: outlier or unique molecular entity?David A Sallman, Eric Padron
Best Practice & Research. Clinical Haematology|June 18, 2019
Current status and new treatment approaches in TP53 mutated AMLAnthony M Hunter, David A Sallman
Current Opinion in Hematology|December 29, 2016
What are the most promising new agents in acute myeloid leukemia?David A Sallman, Jeffrey E Lancet
Current Hematologic Malignancy Reports|November 25, 2019
Mutation-Driven Therapy in MDSDavid M Swoboda, David A Sallman
Best Practice & Research. Clinical Haematology|December 6, 2020
The promise of macrophage directed checkpoint inhibitors in myeloid malignanciesDavid M Swoboda, David A Sallman
Pageof 17

Showing results (11-20 of 164) with videos related to

Sort By:
Pageof 17
Cancer Journal (Sudbury, Mass.)|January 24, 2022
What Are the Prospects for Treating TP53 Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia?Chen Wang, David A Sallman
Current Treatment Options in Oncology|March 25, 2023
Current Therapeutic Landscape in Lower Risk Myelodysplastic SyndromesChen Wang, David A Sallman
Blood|September 5, 2024
TP53-mutated acute myeloid leukemia: how can we improve outcomes?David A Sallman, Maximilian Stahl
Leukemia & Lymphoma|November 26, 2022
Therapeutic approaches for the management of higher risk myelodysplastic syndromesChen Wang, David A Sallman
Hematology. American Society of Hematology. Education Program|December 9, 2023
Frontline treatment options for higher-risk MDS: can we move past azacitidine?David A Sallman, Zhuoer Xie
Haematologica|June 2, 2017
Myelodysplasia in younger adults: outlier or unique molecular entity?David A Sallman, Eric Padron
Best Practice & Research. Clinical Haematology|June 18, 2019
Current status and new treatment approaches in TP53 mutated AMLAnthony M Hunter, David A Sallman
Current Opinion in Hematology|December 29, 2016
What are the most promising new agents in acute myeloid leukemia?David A Sallman, Jeffrey E Lancet
Current Hematologic Malignancy Reports|November 25, 2019
Mutation-Driven Therapy in MDSDavid M Swoboda, David A Sallman
Best Practice & Research. Clinical Haematology|December 6, 2020
The promise of macrophage directed checkpoint inhibitors in myeloid malignanciesDavid M Swoboda, David A Sallman
Pageof 17